BRCA1: Homologous Recombination, Inherited Risk and HRD

The ATM–BRCA1 Signalling Cascade at DNA Double-Strand Breaks

When a DNA double-strand break (DSB) is detected by the MRN complex (MRE11–RAD50–NBS1), ATM kinase is rapidly activated and phosphorylates histone H2AX (γH2AX) across megabase chromatin domains flanking the break. ATM directly phosphorylates BRCA1 at Ser1387 and Ser1423 (within the BRCT domain), enabling BRCA1's recruitment to break sites via the γH2AX→MDC1→RNF8/RNF168→ubiquitin-H2A→RAP80/ABRAXAS pathway. This ATM→BRCA1 signalling axis is the first step in the homologous recombination cascade and the molecular foundation of BRCA1 tumour suppression.

ATM also phosphorylates CHK2 (Thr68), which then phosphorylates BRCA1 at Ser988 — providing a second kinase input reinforcing BRCA1 activation. This redundant ATM→BRCA1 and ATM→CHK2→BRCA1 signalling ensures robust BRCA1 recruitment even in the context of partial ATM loss. Germline BRCA1 mutations that disrupt the BRCT domain (which contains the BRCA1 phosphoserine-binding motifs and is the most commonly mutated region in BRCA1-associated cancer) specifically abrogate this ATM-mediated recruitment — connecting loss of BRCA1 HR function directly to the failure of upstream ATM signalling to engage the repair cascade.

Homologous Recombination: BRCA1's Core Tumour Suppressor Pathway

At the DSB site, BRCA1 performs two critical functions in the HR cascade. First, BRCA1 promotes DNA end resection — the 5′-to-3′ nucleolytic degradation that generates 3′ single-stranded DNA (ssDNA) overhangs essential for HR — by antagonising the competing 53BP1-RIF1 pathway that otherwise directs breaks toward non-homologous end joining (NHEJ). Second, BRCA1 recruits BRCA2 to the break site through its interaction with PALB2 via the BRCA1 coiled-coil domain; BRCA2 then loads RAD51 recombinase onto the RPA-coated 3′ ssDNA, enabling strand invasion into the intact sister chromatid template for high-fidelity repair.

Loss of BRCA1 function can shift double-strand-break repair toward pathways that are more likely to leave deletions, rearrangements or other genomic scars. HRD assays attempt to capture aspects of that phenotype, but platforms use different methods and cut-offs. An HRD score does not by itself identify the causal gene, prove current functional deficiency or establish treatment benefit outside the population and assay in which it was validated.

PARP Inhibitor Synthetic Lethality: Exploiting the Homologous Recombination Defect

The therapeutic exploitation of BRCA1 loss rests on synthetic lethality: simultaneous disruption of two cellular repair pathways that are individually survivable but lethal in combination. BRCA1-deficient cancer cells cannot perform HR, relying on PARP1-mediated single-strand break (SSB) repair as their primary backup for replication-associated DNA damage. PARP inhibitors (olaparib, niraparib, rucaparib, talazoparib) trap PARP1 on DNA as stable covalent PARP-DNA complexes at SSB sites rather than allowing catalytic release after repair.

When replication encounters a PARP-trapping lesion, fork disruption can create DNA structures that require homologous recombination and fork-protection functions. BRCA1-deficient tumour cells may therefore be more vulnerable than repair-proficient cells. Regulatory indications nevertheless differ by cancer, germline versus somatic status, line of therapy, combination and companion test; a mechanistic diagram is not a substitute for the current label.

Inherited-Risk Results and Clinical Follow-Up

A pathogenic or likely pathogenic germline BRCA1 result can change discussions about screening, risk-reducing options and testing of relatives. The appropriate plan depends on age, sex, personal and family history, prior treatment, reproductive goals and local guidance. NCI recommends that results be interpreted with a genetics-trained clinician; a variant of uncertain significance should not be managed as a pathogenic variant.

A BRCA1 alteration first found on tumour testing is not automatically inherited. NCI advises discussing whether germline testing is appropriate because a tumour result can be somatic or germline. Conversely, a negative result can be uninformative when no familial pathogenic variant is known. This page does not prescribe screening intervals or surgery.

BRCA1 vs BRCA2: Distinct Roles, Different Cancer Spectrums

Although both BRCA1 and BRCA2 are essential for homologous recombination, they act at different steps. BRCA1 functions upstream: it promotes DSB end resection to generate 3′ ssDNA overhangs (by antagonising 53BP1-mediated NHEJ) and recruits BRCA2 to the break site through its interaction with PALB2 via a coiled-coil domain. BRCA2 functions downstream: it directly loads RAD51 onto RPA-coated 3′ ssDNA overhangs through its eight BRC repeats and a C-terminal RAD51-binding domain, enabling strand invasion and template-directed repair. Loss of either protein impairs HR, but at mechanistically distinct steps.

Their cancer spectrums reflect these molecular roles. BRCA1 mutations predominantly predispose to triple-negative breast cancer (TNBC) — approximately 70–80% of BRCA1-associated breast cancers are ER/PR/HER2-negative, compared to ~15% in the general population — and to high-grade serous ovarian cancer. BRCA2 mutations predispose to ER-positive breast cancer more similar to sporadic disease, a substantially higher male breast cancer risk (~7% lifetime vs 0.1% general male population), and pancreatic cancer risk (~5–7% lifetime). Germline BRCA2 mutations also occur in ~5% of prostate cancers and confer more aggressive disease biology, explaining why BRCA2 testing is now standard in advanced prostate cancer.

BRCA1 in Triple-Negative Breast Cancer and Platinum Sensitivity

TNBC is the most clinically challenging breast cancer subtype, characterised by high proliferative rate, early visceral metastasis, and absence of targetable hormone receptors or HER2 amplification — leaving chemotherapy as the principal systemic option for most patients. Germline BRCA1 mutations account for ~15–20% of TNBC, and somatic BRCA1 promoter methylation or mutation accounts for an additional ~10–15%, creating a substantial 'BRCAness' subset with HR deficiency beyond germline carriers. BRCA1-mutant TNBC has high homologous recombination deficiency (HRD) scores and characteristic genomic scarring patterns (large deletions, tandem duplications) that serve as biomarkers of HR deficiency.

The OlympiA trial evaluated one year of adjuvant olaparib in a defined population with germline BRCA1/2 variants and high-risk HER2-negative early breast cancer; the primary publication should be used for eligibility criteria and outcome definitions. Separate metastatic trials studied olaparib or talazoparib in germline BRCA1/2-mutated HER2-negative breast cancer. These results should not be combined into one universal statement about every BRCA1 alteration or disease setting.

Key Takeaways

• ·ATM kinase is activated within seconds of DSB detection and directly phosphorylates BRCA1 (Ser1387/1423), initiating the ATM→BRCA1 signalling cascade. BRCA1 then orchestrates homologous recombination upstream — promoting DSB end resection and recruiting BRCA2 via PALB2 — while BRCA2 acts downstream, directly loading RAD51 onto ssDNA for strand invasion.
• ·NCI estimates that more than 60% of women with an inherited harmful BRCA1 or BRCA2 change develop breast cancer; ovarian-cancer estimates differ for BRCA1 and BRCA2 and should be read from the dated source.
• ·PARP inhibitor synthetic lethality exploits BRCA1-deficient cells' dependence on PARP1-mediated SSB repair — PARP trapping converts SSBs to DSBs at replication forks, which cannot be repaired by HR-deficient cells.
• ·PARP-inhibitor evidence is specific to the cancer, biomarker definition, disease stage, prior therapy, regimen and regulatory indication.
• ·Inherited-risk management requires genetics-informed care; tumour-only results, germline results and variants of uncertain significance must not be treated as equivalent.